- Registered in Europe and complies with all EU requirements
- Passed safety study in Europe5
- Polyoxidonium® studies are conducted in accordance with high international standards


Polyoxidonium® is included into guidelines and supported by leading scientific organizations

- children aged 3 years and older
½ of a tablet 1 time a day for 7 days - children aged 10 years and older
1 tablet 1 time a day for 7 days - adults
1 tablet 1 time a day for 10 days

For respiratory viral infections treatment1:
- children aged 3 years and older
½ of a tablet 2 times a day for 7 days - children aged 10 years and older
1 tablet 2 times a day for 7 days - adults
1 tablet 2 times a day for 7 days

Polyoxidonium® to combat respiratory viral infections

Polyoxidonium® can have a combined effect on the course of respiratory viral infections1:
- can decrease disease severity3,
- decreases inflammation4,
- boosts immunity and reduces the number of repeated cases of ARVI6.
Footnotes
- Patient information leaflet for Polyoxidonium®.
- Malanicheva, T.G., Agafonova, E.V. (2018). The effectiveness of immunomodulatory therapy of community-acquired pneumonia in frequently ill children. Children Infections, 17(4), 38–43.
- Garaschenko, T.I., Karneeva, O.V., Tarasova, G.D., et al. (2020). Influence of local application of Polyoxidonium® on symptoms and course of acute respiratory viral infection in children: results of multicenter double-blind placebo-controlled study. Consilium Medicum, 22(3), 80–86.
- Karaulov, A.V., Gorelov, A.V. (2019). The use of azoximer bromide for treatment of inflammatory infections of respiratory system in children: a meta-analysis of controlled clinical studies. Journal of Infectology, vol. 11, No. 4, 31–41.
- Pruzinec, P., Chirun, N., Sveikata, A. (2018). The safety profile of Polyoxidonium® in daily practice: results from postmarketing safety study in Slovakia. Immunotherapy, 10(2), 1–7.
- Kharit, S.M., Galustyan, A.N. (2017). Azoximer bromide is a safe and effective drug for treatment of acute upper respiratory tract infections in children: an overview of the results of double-blind, placebo-controlled, randomized clinical trials of phase II and III. Pediatrics (Appendix to Consilium Medicum), 2.